ProQR Therapeutics NV appointed David Rodman as chief development strategy officer.
Rodman has served as a chief medical officer at miRagen Therapeutics Inc. and Nivalis Therapeutics Inc.
Discover more about S&P Global’s offerings
ProQR Therapeutics appoints chief development strategy officer
Commercial Banking: June 22nd Edition
Understanding Loss Given Default A Review of Three Approaches
Commercial Banking Newsletter June Edition - 2022
Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push
ProQR Therapeutics NV appointed David Rodman as chief development strategy officer.
Rodman has served as a chief medical officer at miRagen Therapeutics Inc. and Nivalis Therapeutics Inc.